BlossomHill Therapeutics Announces Collaboration with Foundation Medicine to Develop First Companion Diagnostic for BH-30643 in EGFR C797S Mutated Non-Small Cell Lung Cancer
BlossomHill Therapeutics announced a collaboration with Foundation Medicine to develop the first companion diagnostic assay for the EGFR C797S resistance mutation, the most common driver of resistance to osimertinib in EGFR-mutant NSCLC. The CDx assay will be validated using the ongoing Phase 1/2 SOLARA trial (NCT06706076) of BH-30643, a macrocyclic mutant-selective OMNI-EGFR inhibitor with Fast Track designation for the C797S population.
Key figures
- Drug Name
- BH-30643
- Phase Of Trial
- Phase 1/2
- Trial Name
- SOLARA
- Trial Sites
- more than 40 sites in 10 countries
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.